Department of Pathology, University of Arizona College of Medicine and College of Pharmacy, Tucson, AZ, USA.
Department of Pharmacology, University of Arizona College of Medicine and College of Pharmacy, Tucson, AZ, USA; College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou 310058, China.
Neurobiol Dis. 2019 Dec;132:104539. doi: 10.1016/j.nbd.2019.104539. Epub 2019 Jul 22.
TAF1/MRSX33 intellectual disability syndrome is an X-linked disorder caused by loss-of-function mutations in the TAF1 gene. How these mutations cause dysmorphology, hypotonia, intellectual and motor defects is unknown. Mouse models which have embryonically targeted TAF1 have failed, possibly due to TAF1 being essential for viability, preferentially expressed in early brain development, and intolerant of mutation. Novel animal models are valuable tools for understanding neuronal pathology. Here, we report the development and characterization of a novel animal model for TAF1 ID syndrome in which the TAF1 gene is deleted in embryonic rats using clustered regularly interspaced short palindromic repeats (CRISPR) associated protein 9 (Cas9) technology and somatic brain transgenesis mediated by lentiviral transduction. Rat pups, post-natal day 3, were subjected to intracerebroventricular (ICV) injection of either gRNA-control or gRNA-TAF1 vectors. Rats were subjected to a battery of behavioral tests followed by histopathological analyses of brains at post-natal day 14 and day 35. TAF1-edited rats exhibited behavioral deficits at both the neonatal and juvenile stages of development. Deletion of TAF1 lead to a hypoplasia and loss of the Purkinje cells. We also observed a decreased in GFAP positive astrocytes and an increase in Iba1 positive microglia within the granular layer of the cerebellum in TAF1-edited animals. Immunostaining revealed a reduction in the expression of the CaV3.1 T-type calcium channel. Abnormal motor symptoms in TAF1-edited rats were associated with irregular cerebellar output caused by changes in the intrinsic activity of the Purkinje cells due to loss of pre-synaptic CaV3.1. This animal model provides a powerful new tool for studies of neuronal dysfunction in conditions associated with TAF1 abnormalities and should prove useful for developing therapeutic strategies to treat TAF1 ID syndrome.
TAF1/MRSX33 智力障碍综合征是一种 X 连锁疾病,由 TAF1 基因的功能丧失突变引起。这些突变如何导致发育异常、低张力、智力和运动缺陷尚不清楚。胚胎期靶向 TAF1 的小鼠模型已经失败,这可能是因为 TAF1 对生存至关重要,在早期大脑发育中优先表达,并且不能耐受突变。新型动物模型是理解神经元病理学的有价值的工具。在这里,我们报告了一种新型 TAF1 智力障碍综合征动物模型的开发和表征,该模型使用 CRISPR 相关蛋白 9 (Cas9) 技术和通过慢病毒转导介导的体细胞脑转基因在胚胎大鼠中删除 TAF1 基因。出生后第 3 天的幼鼠接受脑室内 (ICV) 注射 gRNA-对照或 gRNA-TAF1 载体。对大鼠进行一系列行为测试,然后在出生后第 14 天和第 35 天进行大脑组织病理学分析。TAF1 编辑的大鼠在新生儿和青少年阶段都表现出行为缺陷。TAF1 的缺失导致小脑浦肯野细胞的发育不良和丢失。我们还观察到 TAF1 编辑动物小脑颗粒层中 GFAP 阳性星形胶质细胞减少和 Iba1 阳性小胶质细胞增加。免疫染色显示 CaV3.1 T 型钙通道的表达减少。TAF1 编辑大鼠的异常运动症状与由于浦肯野细胞内在活性的改变导致的小脑输出异常有关,这种改变是由于突触前 CaV3.1 的丢失引起的。这种动物模型为研究与 TAF1 异常相关的神经元功能障碍提供了一种强大的新工具,并且应该有助于开发治疗 TAF1 智力障碍综合征的治疗策略。